Table 3 with references. Genes identified in this study previously implicated in cancer

Affymertix
ID / Gene
Symbol / Involvement in cancer / Reference
1p arm
202178_at / PRKCZ / glioblastoma; critical for proliferation / 1
1555370_a_at / CAMTA1 / neuroblastoma; down-regulation linked to poor survival / 2, 3
205277_at / PRDM2 / pheochromocytoma, AML; down-regulated / 4, 5
231110_at / FABP3 / breast cancer; candidate tumour suppressor gene / 6
208634_s_at / MACF1 / neuroblastoma; disrupted by translocation / 7
208924_at / RNF11 / breast cancer; highly expressed / 8
227123_at / RAB3B / megakaryoblastic leukaemia, pancreatic carcinoma; upregulated
during differentiation / 9, 10
202741_at / PRKACB / ovarian cancer; down-regulated / 11
209090_s_at / SH3GLB1 / HeLa cells; pro-apoptotic, loss may contribute to tumorigenesis / 12
4p arm
209492_x_at / ATP5I / hepatocellular carcinoma, ovarian cancer; upregulated / 10, 13
40225_at / GAK / prostate cancer hormone refractory; ; upregulated / 14
213980_s_at / CTBP1 / may act as an oncogene / 15
206052_s_at / SLBP / required for progression through the cell cycle / 16
218308_at / TACC3 / multiple myeloma; co-ordinately upregulated with WHSC1
ovarian cancer; upregulated in chemoresistant tumours / 17, 18
222778_s_at / WHSC1 / multiple myeloma; up-regulation linked to poor prognosis / 17
224416_s_at / MED28 / various cancers; stimulates cellular proliferation / 19
218662_s_at / HCAP-G / pancreatic cancer; ; up-regulation contributes to cells motility / 20
235554_x_at / MGC29898 / glioblastoma; amplified / 21
223414_s_at / LYAR / Leukaemia; upregulated, may regulate cell growth / 22
201385_at / DHX15 / MPNSTs and Barrett's carcinoma; copy number gains / 23, 24
225014_at / LOC389203 / glioblastoma; amplified and over-expressed / 21
207785_s_at / RBPSUH / gastrointestinal carcinoid cells; activation of Notch signalling / 25
203343_at / UGDH / ovarian carcinoma; associated with CDDP-resistance / 26
230896_at / CCDC4 / neuroblastoma; up-regulation linked to poor survival / 27
17q arm
212281_s_at / MAC30 / meningioma and other cancers; upregulated / 28, 29
204531_s_at / BRCA1 / breast and ovarian cancers; mutated / 30
211603_s_at / ETV4 / Ewing sarcoma, prostate cancer; fusion gene / 31, 32
208835_s_at / CROP / cloned from cisplatin-resistant cell lines / 33
201577_at / NME1 / neuroblastoma; up-regulation in advanced stages; poor prognosis / 34, 35
221703_at / BRIP1 / interacts with BRCA1 / 36
211762_s_at / KPNA2 / breast cancer, melanoma; poor prognostic marker / 37, 38
64.4 Mb to qtel
204868_at / ICT1 / colon carcinoma; down-regulated during the in vitro differentiation / 39
217932_at / MRPS7 / osteosarcoma; enriched mRNAs compared to normal osteoblasts / 40
212723_at / PTDSR / glioblastoma; poor prognostic marker / 41
200753_x_at / SFRS2 / increased expression during mouse fibroblasts transformation / 42
1554408_a_at / TK1 / proliferation marker in a number of tumours / 43, 44
202095_s_at / BIRC5 / neuroblastoma; over-expression linked to poor prognosis / 45
201303_at / DDX48 / variety of cancers; auto-antibodies to DDX48 / 46
203931_s_at / MRPL12 / ovarian cancer; upregulated / 11
200656_s_at / P4HB / HER-2/neu-positive breast cancer, melanoma; ; upregulated / 47, 48
226414_s_at / ANAPC11 / osteosarcoma; enriched mRNAs compared to normal osteoblasts / 40
202148_s_at / PYCR1 / ovarian cancer; upregulated ; anti-apoptotic / 10, 49
MYCN
co-amplified
201241_at / DDX1 / neuroblastoma, co-amplified with MYCN / 50
205862_at / GREB1 / breast cancer; suppression blocks estrogen induced growth / 51
212274_at / LPIN1 / neuroblastoma, co-amplified with MYCN / 52
200790_at / ODC1 / neuroblastoma, co-amplified with MYCN / 53
209773_s_at / RRM2 / pancreatic cancer; therapeutic target / 54
216941_s_at / TAF1B / MSH-I colorectal carcinoma; mutated in 82% of tumours / 55

(1) Donson AM, Banerjee A, Gamboni-Robertson F, Fleitz JM, Foreman NK. Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines.
J Neurooncol 2000;47:109-15.

(2) Henrich KO, Fisher M, Mertens D, Benner A, Wiedemeyer R, Brors B et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 2006;12:131-8.

(3) Asgharzadeh S, Pigue-Regi R, Sposto R, Wang H, Yang Y, Shimada H et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. JNCI 2006;98:1193-1203.

(4) Geli J, Nord B, Frisk T, Edstrom Elder E, Ekstrom TJ, Carling T et al. Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas. Int J Oncol 2005;26:1385-91.

(5) Sasaki O, Meguro K, Tohmiya Y, Funato T, Shibahara S, Sasaki T. Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia. Br J Haematol 2002;119:940-8.

(6) Huynh HT, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 1995;55:2225-31.

(7) Schleiermacher G, Bourdeaut F, Combaret V, Pierron G, Raynal V, Aurias A et al. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene 2005;24:3377-84.

(8) Azmi P, Seth A. RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation. Eur J Cancer 2005;41:2549-60.

(9) Nagata K, Okano Y, Nozawa Y. Differential expression of low Mr GTP-binding proteins in human megakaryoblastic leukemia cell line, MEG-01, and their possible involvement in the differentiation process. Thromb Haemost 1997;77:368-75.

(10) Klengel R, Piiper A, Pittelkow S, Zeuzem S. Differential expression of Rab3 isoforms during differentiation of pancreatic acinar cell line AR42J.Biochem Biophys Res Commun 1997;236:719-22.

(11) Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;6:10602-12.

(12) Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol 2005;25:9369-82.

(13) Ying H, Yu Y, Xu Y. Antisense of ATP synthase subunit e inhibits the growth of human hepatocellular carcinoma cells. Oncol Res 2000;12:485-90.

(14) Ray MR, Wafa LA, Cheng H, Snoek R, Fazil L, Gleave M et al. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 2006;118:1108-19.

(15) Paliwal S, Pande S, Kovi RC, Sharpless NE Bardeesy N, Grossman SR. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 2006;26:2360-72.

(16) Zhao X, McKillop-Smith S, Muller B. The human histone gene expression regulator HBP/SLBP is required for histone and DNA synthesis, cell cycle progression and cell proliferation in mitotic cells. J Cell Sci 2004;117:6043-51.

(17) Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TRJ, Shaughnessy J. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 2004;126:72-6.

(18) L’Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006;29:5-24.

(19) Lu M, Zhang L, Maul RS, Satrippour MR, Norris A, Whitelegge J et al. The novel gene EG-1 stimulates cellular proliferation. Cancer Res 2005;65:6159-66.

(20) Thompson CC, Ashocroft FJ, Patel S Saraga G, Vimakachandran D, Prime W et al. Pancreatic cancer cells overexpress gelsolin family capping proteins which contribute to their cell motility. Gut 2006; on line.

(21) Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, Gomez E et al. Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer 2006;26:39.

(22) Su L, Hershberger RJ, Weissman IL. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. Genes Dev 1993;7:735-48.

(23) Nakagawa Y, Yoshida A, Numoto K, Kunisada T, Wai D, Ohata N et al. Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. Oncol Rep 2006; 15:297-303.

(24) Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert JR, Hopt U et al. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 2004;203:780-8.

(25) Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G636-42.

(26) Konno R. Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray. Hum Cell 2001; 4:261-6.

(27) Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91.

(28) Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterisation of genes differentially expressed in meningiomas. Cell Growth Differ 1993; 4:715-22.

(29) Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol 2004;19:1021-31.

(30) Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006;6:1416-26.

(31) Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 1996;15:608-12.

(32) Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;1:3396-400.

(33) Nishii Y, Morishima M, Kakehi Y, Umehara Y, Kioka N, Terano Y et al. CROP/Luc7A, a novel serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line. FEBS Lett. 2000;14:153-6.

(34) Hailat N, Keim DR, Melhem RF, Zhu X, Eckerskorn C, Brodeur GM et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991;88:341-5.

(35) Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Benwargen B et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005;24:7902-12.

(36) Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001;105:149-60.

(37) Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006;12:3950-60.

(38) Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. I Natl Cancer Inst 2006;98:472-82.

(39) Van Belzen N, Dinjens WN, Eussen BH, Bosman FT. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol. 1998;13:1233-42.

(40) Olstad OK, Gautvik VT, Reppe S, Rian S, Jemtland R, Ohlsson C et al. Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning. Anticancer Res 2003;23:2201-16.

(41) Dong S, Nutt CL, Betensky RA, Stemmer-Rachaminov AO, Denko NC, Ligon KL et al. Histology-based expression profiling yelds novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol 2005;64:948-55.

(42) Maeda T, Furukawa S. Transformation-associated changes in gene expression of alternative splicing regulatory factors in mouse fibroblast cells. Oncol Rep 2001;8:563-6.

(43) He Q, Zhang P, Zou L, Li H, Wang X, Zhou S et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proloferation marker in human solid tumors than its activity. Oncol Rep 2005;14:1013-9.

(44) Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 2006;15:455-61.

(45) Miller MA, Ohashi K, Zhu X, McGrady P, London W, Hogarty M et al. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: A Report From the Children's Oncology Group. J Pediatr Hematol Oncol 2006;28:412-7.

(46) Xia Q, Kong XT, Zhang GA, Hou XJ, Qiang H, Zhong RQ. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005;330:526-32.

(47) Zhang D, Tai LK, Wong LL, Chiu LL, SethiSK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005;4:1686-96.

(48) Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D’Atri S et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005;15:235-44.

(49) Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-80.

(50) Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J et al. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995;6:1417-22.

(51) Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat. 2005;92:141-9.

(52) Weber A, Imisch P, Bergmann E, Christiansen H. Co-amplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004;22:2681-90.

(53) Tonin PE, Yeger H, Stallings RL, Srinivasan PR, Lewis WH. Amplification of N-myc and ornithine decarboxylase genes in human neuroblastoma and hydroxyurea-resistant hamster cell lines. Oncogene 1989;4:1117-21.

(54) Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery 2004;136:261-9.

(55) Kim NG, Rhee H, Li LS, Kim H, Lee JS, Kim JH et al. KiIdentification of MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal carcinomas with microsatellite instability. Oncogene 2002;21:5081-7.